Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid.
The glucuronidation kinetics of the prototypic substrates 4-methylumbelliferone (4MU) and 1-naphthol (1NP) by human UDP-glucuronosyltransferases (UGT) 1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B7, 2B15, and 2B17 were investigated. Where activity was demonstrated, inhibitory effects of diclofenac, probenecid, and the solvents acetone, acetonitrile, dimethyl sulfoxide, ethanol, and methanol were characterized. All isoforms except UGT1A4 glucuronidated 4MU, whereas all but UGT 1A4, 2B15, and 2B17 metabolized 1NP. However, kinetic models varied with substrate (for the same isoform) and from isoform to isoform (with the same substrate). Hyperbolic (Michaelis-Menten), substrate inhibition, and sigmoidal kinetics were variably observed for both 4MU and 1NP glucuronidation by the various UGTs. K(m) or S(50) (sigmoidal kinetics) and V(max) values varied 525- (8-4204 microM) and 1386-fold, respectively, for 4MU glucuronidation, and 1360- (1.3-1768 microM) and 37-fold, respectively, for 1NP glucuronidation. The use of a two-site model proved useful for those reactions exhibiting non-Michaelis-Menten glucuronidation kinetics. The organic solvents generally had a relatively minor effect on UGT isoform activity. UGT 2B15 and 2B17 were most susceptible to the presence of solvent, although solvent-selective inhibition was occasionally observed with other isoforms. Diclofenac and probenecid inhibited all isoforms, precluding the use of these compounds for the reaction phenotyping of xenobiotic glucuronidation pathways in human tissues. Diclofenac and probenecid K(i) values, determined for selected isoforms, ranged from 11 to 52 microM and 96 to 2452 microM, respectively. Overall, the results emphasize the need for the careful design and interpretation of kinetic and inhibition studies with human UGTs.
Uchaipichat
Verawan
V
Department of Clinical Pharmacology, Flinders Medical Centre, Bedford Park, SA 5042, Australia. john.miners@flinders.edu.au
Mackenzie
Peter I
PI
Guo
Xiao-Hui
XH
Gardner-Stephen
Dione
D
Galetin
Aleksandra
A
Houston
J Brian
JB
Miners
John O
JO
D000096:Acetone / Q000494:pharmacology; D000818:Animals; D015153:Blotting, Western / Q000379:methods; D018938:Caco-2 Cells; D004008:Diclofenac / Q000494:pharmacology*; D004121:Dimethyl Sulfoxide / Q000494:pharmacology; D000431:Ethanol / Q000494:pharmacology; D005965:Glucuronates / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000493:pharmacokinetics*; D014453:Glucuronosyltransferase / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000494:pharmacology*; D006801:Humans; D006923:Hymecromone / Q000031:analogs & derivatives* / Q000378:metabolism / Q000493:pharmacokinetics*; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000494:pharmacology*; D007700:Kinetics; D000432:Methanol / Q000494:pharmacology; D051379:Mice; D011339:Probenecid / Q000494:pharmacology*; D012997:Solvents / Q000737:chemistry / Q000494:pharmacology
D005965:Glucuronates; D007527:Isoenzymes; D012997:Solvents; D000096:Acetone; D004008:Diclofenac; D000431:Ethanol; D006923:Hymecromone; C029091:naphthyl glucuronide; C043647:4-methylumbelliferyl-6-sulfo-2-acetamido-2-deoxy-beta-glucopyranoside; D014453:Glucuronosyltransferase; D011339:Probenecid; D000432:Methanol; D004121:Dimethyl Sulfoxide